Physician profile
Khalid B Khan
NPI 1063440840
$9,386.89
in general payments reported to CMS, 2019-2025
32 companies · $876 in 2025
The $876 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,376 · 2020: $969 · 2021: $2,340 · 2022: $1,704 · 2023: $1,209 · 2024: $913 · 2025: $876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,978 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,977.51 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,467.83 | 2019-2025 | Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $1,189.81 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $1,028.86 | 2021-2025 | |
| Amgen INC. | $586.00 | 2021-2025 | Repatha, Otezla, Repatha |
| Horizon Therapeutics Plc | $495.39 | 2019-2023 | Tepezza |
| Abbvie INC. | $473.19 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $452.90 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $418.03 | 2020-2022 | |
| Pfizer INC. | $384.37 | 2019-2024 | |
| Novo Nordisk INC | $359.48 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $340.71 | 2019-2023 | Verquvo, Belsomra |
| Sanofi-Aventis U.S. LLC | $290.87 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.45 | 2020-2025 | Jardiance |
| Lilly USA, LLC | $268.27 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Redhill Biopharma INC. | $257.62 | 2020-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $192.27 | 2020-2025 | Trelegy Ellipta |
| Daiichi Sankyo INC. | $131.02 | 2019 | |
| Novartis Pharmaceuticals Corporation | $128.68 | 2021-2023 | |
| Dexcom, INC. | $92.69 | 2022-2023 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $86.25 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $76.22 | 2019-2020 | |
| Exact Sciences Corporation | $59.10 | 2023-2024 | Cologuard Collection Kit |
| Abbott Laboratories | $49.40 | 2022-2023 | Freestyle Libre 2 |
| Phathom Pharmaceuticals, INC. | $49.09 | 2024 | Voquezna |
| Eisai INC. | $43.38 | 2020 | |
| Medtronic, INC. | $42.55 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $42.04 | 2021 | |
| Allergan, INC. | $29.37 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.69 | 2022 | |
| Genentech USA, INC. | $24.48 | 2021 | |
| Amarin Pharma, INC. | $16.84 | 2020 | |
| Shield Therapeutics INC | $15.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.